TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: STIMULATE Study: Anemia Correction and Health-related Quality of Life (HRQoL) Outcomes in Elderly Chronic Kidney Disease (CKD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage 3-5 CKD not on dialysis~* Patients ≥ 70 years of age~* Haemoglobin \< 110g/L at screening~* Transferrin saturation ≥ 15% at screening~Exclusion Criteria:~* Clinical history of type 2 diabetes mellitus~* Anticipating or scheduled to go on renal replacement therapy in the next year, including renal transplant~* Uncontrolled hypertension on two separate measurements during screening~* Use of any erythropoietic protein within 12 weeks of screening

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
- Placebo (Type: PLACEBO_COMPARATOR): Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Functional Outcomes at 2 Months According to Therapeutic Management, in Trauma With Low-grade Osteo-ligamentous Ankle Injury in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Walking child from 5 to 15 years old.~* From hour 0 to hour 48 of ankle trauma with torsion mechanism (inversion, eversion or rotation).~* Patient presenting for the first time to the emergency room for this traumatic episode.~* Possibility of carrying out an ultrasound during the passage to the emergency room.~* Child and parents' consent in the study participation~Exclusion Criteria:~* Pubescent patients requiring anticoagulation (menarche in girls and genital pilosity in boys).~* Direct shock on the foot without sprain mechanism.~* Fracture with deformation or open fracture.~* History of ankle trauma in the last 3 months.~* Neurological or neuromuscular pathology.~* Child with a delay in acquisitions and / or psychomotor development (difficulties in understanding and interacting to locate pain).~* Absence of a representative of parental authority.~* Constitutional bone disease or connective tissue.~* Acquired or congenital coagulopathy.~* Patient presenting beyond 48h of trauma.~* Polytraumatized.~* Dermabrasion, wound or sign of skin suffering next to the ankle requiring specific monitoring.~* Child or parents refusal in study participation

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Below-knee soft resin cast (Type: EXPERIMENTAL): Below-knee soft resin cast is administered to participants in emergency department. Investigator puts three layers of jersey supplemented by strips of soft resins to be unrolled along the leg after immersion in warm water~Duration to ankle immobilization with soft resin boot : 21 days.
- Below-knee rigid resin cast (Type: OTHER): Below-knee soft resin cast is administered to participants in emergency department. Investigator puts one layer of jersey and then one layer of foam composed by strips of cotton wool to be unrolled supplemented by strips of rigid resins to be unrolled along the leg after immersion in warm water.~Duration to ankle immobilization with soft resin boot : 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motivational Interviewing for HCV Elimination

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patient Inclusion Criteria:~* Willingness to participate and provide informed consent~* Positive HCV RNA Result~* ≥18 years of age~Patient Exclusion Criteria:~* Unwilling or unable to provide consent~Health Care Provider Inclusion Criteria:~* Willingness to participate and provide informed consent~* Has a hepatitis C care experience~Health Care Provider Exclusion Criteria:~* Unwilling or unable to provide consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Motivational Interviewing Training (Type: ACTIVE_COMPARATOR): Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
- Standard Clinical Encounter (Type: NO_INTERVENTION): Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed, and dated informed consent as defined by the Institutional Review Board.~* Male and female patients older than 18 years of age undergoing primary elective hip, knee or shoulder arthroplasty.~* Documented nasal carriage of MRSA.~* If a female of childbearing potential the patient should agree to practice a reliable contraceptive method (e.g. birth control pills, condoms, or intrauterine device \[IUD\]) during treatment and for one month after receiving the study medication.~Exclusion Criteria:~* Concurrent urinary tract infection or colonization unless treated with evidence of microbiologic cure.~* Evidence of active infection elsewhere other than urinary tract, unless treated with evidence of microbiologic cure documented by the infectious diseases service.~* Patients undergoing elective secondary arthroplasty.~* Concurrent open wounds~* Pregnant and nursing women (if patient is still of childbearing potential, a negative serum pregnancy test will be confirmed).~* History of allergy or contraindication to study drugs.~* Weight \>150 kg or \<50kg~* Patients with creatinine clearance (CLcr) \< 30ml/min (calculated using the Cockcroft-Gault equation using ideal body weight)~* Severe neutropenia (absolute neutrophil count \<0.500x103 /µl).~* Patients considered unlikely to comply with study procedures or to return for the scheduled post treatment evaluation.~* Ongoing antibiotic therapy for active infection that is anticipated to continue until the day of surgery.~* Any other condition that in the opinion of the investigator, would confound or interfere with evaluation of safety or efficacy of the investigational medication, or prevent compliance with the study protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin (Type: EXPERIMENTAL): Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
- Vancomycin (Type: ACTIVE_COMPARATOR): Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patients not eligible for surgical resection, liver transplantation, local ablation techniques or chemoembolisation and with histologically proven liver carcinoma whenever possible or combination of radiologically documented hypervascular liver tumour and α foeto protein level ≥ 400 ng/ml~* Signed and dated approved patient informed consent form prior to enrollment into the study~Exclusion Criteria:~* ECOG performance status \> 2~* Inadequate organ function:~  * Neutrophils (ANC) \< 1,500/mm3~ * Hemoglobin \< 10g/dl~ * Platelets \< 100,000/mm3~ * Total bilirubin \> 1.5 x ULN~ * ASAT, ALAT \> 3 x ULN~ * Creatininemia \> 1.5 x ULN (or ≥ 2.0 mg/dl)~ * INR \> 1.6~ * Liver cirrhosis Child Pugh B or C (score \> 6)~ * HbA1C \> 8%~* No measurable or evaluable tumoral lesion~* Patients not eligible for sorafenib therapy and for whom this therapy cannot be postponed by 3 weeks (during AVE1642 single treatment period) in dose escalation part~* Prior exposure to an anti-IGF-1R class compound~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose Level -1 (Type: EXPERIMENTAL): 0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 1 (Type: EXPERIMENTAL): 1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 2 (Type: EXPERIMENTAL): 3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 3 (Type: EXPERIMENTAL): 6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 4 (Type: EXPERIMENTAL): 12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Dose Level 5 (Type: EXPERIMENTAL): 18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
- Combination cohort 1 (Type: EXPERIMENTAL): AVE1642 selected dose in combination with sorafenib
- Combination cohort 2 (Type: EXPERIMENTAL): AVE1642 selected dose in combination with erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed non-small cell lung cancer (squamous cell, large cell, adenocarcinoma, or some combination of these), with clinical or pathological stage III or IV, or recurrent disease; and~2. Hemoglobin level at or below 120 g/L; and~3. At least 18 years of age;~Exclusion Criteria:~1. Systemic platinum-based chemotherapy for lung cancer during the previous two months or planned platinum-based chemotherapy within the next three months;~2. Patients previously treated with high dose thoracic radiation (\>10 fractions), or surgery, without objective evidence of disease recurrence;~3. Planned high dose thoracic radiation therapy (\>10 fractions);~4. A clinically active malignancy, other than the underlying lung cancer which is expected to influence QoL;~5. Expected survival of three months or less;~6. ECOG Performance status of 3 or 4 (see Appendix D);~7. Multiple CNS metastasis or a single CNS lesion that does not demonstrate radiographic stability (Screening CT of head required only if symptomatic, no radiographic follow-up of single resected lesions required);~8. Blood transfusions within the last 14 days;~9. Previous use of erythropoietin;~10. Anemia due to factors other than cancer / radiotherapy (e.g. hemolysis or gastrointestinal bleeding);~11. Evidence of untreated folate or vitamin B12 deficiency;~12. History of uncontrolled hypertension or diastolic blood pressure greater than 100 mm Hg;~13. History of seizure disorder;~14. Known hypersensitivity to mammalian cell-derived products, albumin or any component of the study drug;~15. Pregnancy, lactation or parturition within the previous 30 days;~16. Unwillingness or inability to complete the required QoL questionnaires;~17. Mental incompetence, including psychiatric or addictive disorders which would preclude meaningful completion of questionnaires;~18. Geographically inaccessible for treatment or follow-up evaluations;~19. Currently enrolled in an ongoing therapeutic study;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Nonarthritic Hip Disease Evaluation And Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~Over 18 years old NAHD diagnosis~Exclusion Criteria:~* Osteoporosis or rheumatoid arthritis~* Systemic health condition~* Legal representative required for treatment decisions~* Bilateral symptoms~* Current spine, hip, knee, or ankle surgery or major injury\*~* Pregnancy~* Total hip arthroplasty candidate (Tönnis grade \> 2)~* Periacetabular osteotomy candidate (lateral center edge angle\<20, anterior center edge angle\<18, acetabular index \>10)~  * Participants with history of spine, hip, knee, or ankle surgery or major injury will be evaluated by the physician to determine appropriateness for evaluation (and treatment) by a physical therapist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interdisciplinary Evaluation (Type: EXPERIMENTAL): Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
- Standard Evaluation (Type: NO_INTERVENTION): Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
- Posture and Movement Training (Type: EXPERIMENTAL): Participants will receive six training sessions with a physical therapist over a 3-week period.
- 3-week Wait Period (Type: NO_INTERVENTION): Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
- Observational Arm (Type: OTHER): Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verified allergic sensitivity to either Timothy Grass or Short Ragweed pollen (primary allergen)~* Verified allergic sensitivity to at least one allergen in addition to the primary allergen~Exclusion Criteria:~* Negative skin testing to Timothy Grass or Short Ragweed pollen and at least one other environmental allergen~* Dermatographism~* Severe dermatologic condition that may interfere with skin testing~* Pregnancy~* H1 receptor antihistamine taken within 7 days of testing~* Systemic steroids~* Omalizumab taken at any time in the past~* Receiving or received allergen immunotherapy~* Desensitized to any drug within 6 months~* Current uncontrolled or severe asthma~* Eosinophilic esophagitis~* Significant pulmonary, cardiovascular, renal, hepatobiliary, or neurological diseases, or another disease process felt to put a subject at increased risk for adverse events~* Hypersensitivity to any of the inactive ingredients in the allergen extract tablets~* History of mental illness or drug or alcohol abuse that could interfere with the ability to comply with study requirements~* Inability or unwillingness to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- sublingual allergen tablets (Type: EXPERIMENTAL): Subjects will be administered a sublingual allergen tablet customized to their individual allergic sensitization.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will be administered placebo sublingual tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 20 years old~* Patients who are hospitalized and expected to undergo PCI for acute coronary syndrome, including acute myocardial infarction and unstable angina.~Exclusion Criteria:~* Age \> 80 years~* Cardiogenic shock or unstable patients~* Increased risk of bleeding, anemia, thrombocytopenia~* A need for oral anticoagulation therapy~* Pregnant women or women with potential childbearing~* Life expectancy \< 1 year

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor Arm (Type: EXPERIMENTAL): Ticagrelor Arm
- Clopidogrel Arm (Type: ACTIVE_COMPARATOR): Clopidogrel Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with end stage renal disease and drug-resistant blood pressure.~Exclusion Criteria:~* pregnancy~* secondary hypertension~* unstable coronary artery disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Renal nerve denervation (Type: EXPERIMENTAL): Renal nerve denervation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women 18-40 years old~* Participants will be pregnant women estimated to be between 6 and 20 weeks into their pregnancy~* Pregnant women have smoked at least at least one cigarette in the prior 7 days~* Own a smartphone capable of delivering and receiving text messages~Exclusion Criteria:~* Project materials and text messages are in English, potential participants will be excluded if they cannot read English and if there are concerns about the ability to comprehend or comply with study procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- no CO monitor (Type: EXPERIMENTAL): Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
- CO monitor (Type: EXPERIMENTAL): Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality in Labor and Delivery for Reduction in Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. \>18 years old~3. Pregnant with term gestation~4. Nullipara~5. Pain due to contractions rated from 4-7~6. Contractions at least every 5 minutes x 30 minutes preceding~7. Pain scores obtained at least every 60 minutes~Exclusion Criteria:~1. Parous~2. Use of intravenous medications for pain relief prior to the intervention~3. Use of an epidural~4. Preterm gestation~5. Pain not due to contractions~6. Pain score of 3 or below or 8 or above

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Latent-Control (Type: NO_INTERVENTION): Patients in the latent phase of labor who will receive no intervention.
- Latent-Virtual Reality (VR) (Type: EXPERIMENTAL): Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues